WHO Pharmaceuticals Newsletter No. 4, 2016

OMS, 16 de agosto de 2016

Indice

Asuntos regulatorios
Alphalipoicacid. 5
Apixaban. 5
Benzoylperoxide.. 5
Bisphosphonates 5
Bromhexine-containingcough and cold medicines. 6
Canagliflozin and dapagliflozin 6
Carmustine (intracerebralimplant) 6
Diclofenac. 7
Febuxostat 7
Fingolimod. 7
Hydroxyzine 7
Idelalisib 8
Interferon beta-1a. 8
Lercanidipine.. 9
Levetiracetam. 9
Natalizumab 9
Nintedanib. 10
Ombitasvir, paritaprevir and ritonavircombination 10
Oxytocin.. 10
Rivaroxaban, dabigatran and apixaban. 10
Sodium-glucose cotransporter-2 (SGLT2) inhibitors.. 11
Sofosbuvir. 11
Vemurafenib. 11
Warfarin.. 12

Seguridad demedicamentos
Aspirin-containingover-the-counterantacidproducts 13
Canagliflozin. 13
Citalopram. 13
Denosumab.. 13
Doxylamine and pyridoxinecombination.. 14
Etonogestrelimplants (Nexplanon®) 14

Loperamide.. 15
MarcainSpinal 0.5% Heavy®.. 15
Metformin 15
Miconazole (topical use including oral gel). 16
Zecuity® (sumatriptan) migrainepatch.. 16

Señales
Thiamazole and rhabdomyolysis.. 17

Crónicas
ReportfromtheThirteenth Meeting of the WHO AdvisoryCommitteeon Safety of Medicinal Products(ACSoMP) 23

Disponible en http://bit.ly/2b1yWdh